Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

The hypothesize is that tepotinib is more effective than the investigator's choice of treatment in patients with MET-mutated NSCLC who have progressed after at least one first-line treatment. The main benefit concerns patient access to tepotinib. There is currently no access to a new-generation MET TKI in France for METex14 patients, due to lack of comparative data. There are no phase III RCTs underway anywhere in the world. This study is the only opportunity, perhaps the last, to generate comparative data which, if positive, will enable the drug to be reimbursed. With this in mind, the metho

Trial Details

NCT ID

NCT06908993

Phase

PHASE3

Sponsor

Intergroupe Francophone de Cancerologie Thoracique

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Tepotinib
Pemetrexed (Alimta)
Vinorelbine
Gemcitabine alone
Docetaxel
Paclitaxel

Locations (sample)

Besançon, France|47.24878,6.01815
Bordeaux, France|44.84124,-0.58046
Brest, France|48.39029,-4.48628
Caen, France|49.18585,-0.35912
Créteil, France|48.79266,2.46569

Key Eligibility Criteria

Informed, written and signed consent:
Patients must have signed and dated the written informed consent form approved by the ethics committee in accordance with the legal and institution…
It must have been signed before protocol-related procedures that are not part of normal patient management are performed. Patients should be willin…
Histologically proven advanced NSCLC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →